BURLINGAME, Calif., July 11,
2022 /PRNewswire/ -- Halo Labs, a leading life
science instrumentation company announced it has raised
$6M in series C financing. The round
was led by Agilent Technologies Inc. and includes participation
from existing investors Research Corporation Technologies, Broad
Oak Capital Partners, BioAdvance, and members of the Board of
Directors and senior management.
"We are excited to have Agilent as a
partner in this journey as we scale our business in some exciting
new directions."
This new funding will be used for continued commercialization of
Halo Labs' Aura™ platform, increasing manufacturing capacity and
developing innovative new products to meet the current and new
needs of pharmaceutical researchers.
"For the past two years, Halo Labs has deployed an aggressive
growth strategy and has raised the bar for innovation in our
market," said Rick Gordon, CEO of
Halo Labs. "The fact that we were able to close on a funding round
in the current economic environment demonstrates the success of
that strategy. Our instruments have been adopted by virtually every
major biopharmaceutical company and are now one of the leading
tools in cell and gene therapy. With this capital, we will continue
our current trajectory and scale our business in some exciting new
directions. We are excited to have Agilent as a partner in that
journey."
First launched in 2017, Aura from Halo Labs has disrupted
pharmaceutical product development by combining multiple stability,
quality, and safety assays into one instrument. Now available in
six different models, representing tools specific for different
therapeutic modalities and development stages, Aura instruments
give pharmaceutical scientists access to an unprecedented amount of
data in a matter of minutes, allowing for new therapies to move
from the lab to the clinic faster and more safely.
About Halo Labs
Halo Labs in Burlingame, CA is
a venture-backed scientific instrumentation and consumable company
that commercializes high throughput aggregate, visible and
subvisible particle analysis for biopharmaceutical formulation,
stability, and product quality control using state-of-the-art
custom optics and image processing techniques. Researchers around
the globe depend on Halo Labs for unprecedented insights into
aggregates and subvisible particles present in their drug products
via optical imaging on membranes. For more information, visit
www.halolabs.com.
About Agilent
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent's full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.32 billion in
fiscal 2021 and employs 17,000 people worldwide. Agilent's
Early-Stage Partnerships program (ESP) works with startup companies
to provide them with support and industry partnerships while
providing strategic long-term value to Agilent. Information about
Agilent is available at www.agilent.com.
Contact
Halo Labs
Steven Le
Director of Marketing
info@halolabs.com
Aura is a trademark of Halo Labs in the United States. All rights reserved.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halo-labs-completes-6m-series-c-growth-financing-301583346.html
SOURCE Halo Labs